CA2484184C - Minoxidil foam formulation - Google Patents
Minoxidil foam formulation Download PDFInfo
- Publication number
- CA2484184C CA2484184C CA2484184A CA2484184A CA2484184C CA 2484184 C CA2484184 C CA 2484184C CA 2484184 A CA2484184 A CA 2484184A CA 2484184 A CA2484184 A CA 2484184A CA 2484184 C CA2484184 C CA 2484184C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- minoxidil
- surfactant
- nozzle
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4993—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Abstract
A pharmaceutical dosage form comprises an active ingredient selected from the group consisting of:- minoxidil, minoxidil sulphate, other soluble minoxidil salts and mixtures thereof; a surfactant; water; and optional further excipients; the formulation being adapted to form a foam when administered by spraying.
Description
MINOXIDIL FOAM FORMULATION
This invention relates to a formulation of the pharmaceutical substance minoxidil.
Minoxidil is used for treatment of hereditary hair loss. Previously known formulations comprise a lotion applied using a dropper or by a roller. Minoxidil is sparingly soluble in water and current products comprise propylene glycol, ethanol and water. Such formulations are awkward to administer and thorough coverage of the area to be treated can be difficult.
According to a first aspect of the present invention a pharmaceutical dosage form comprises an active ingredient selected from the group consisting of:-minoxidil, minoxidil sulphate, other soluble minoxidil salts and mixtures thereof;
a surfactant;
water; and optional further excipients;
the formulation being adapted to form a foam when administered by spraying.
Percentages and amounts referred to in the specification are by weight unless stated otherwise. Percentages are selected to total 100%
Dosage forms in accordance with this invention confer several advantages. The absence of ethanol and aerosol prapellents reduces the risk of flammability. Ethanol can be an irritant to a user's skin. The absence of halocarbon aerosol propellents is beneficial to the environment.
Preferably the amount of active ingredient is about 2-5%
Preferably the amount of surfactant is about 2-10% Any combination of anionic, cationic, non-ionic or amphoteric surfactants and non-ionic block copolymers may be used.
Preferably ethoxylated glycerides, ethoxylated sorbitan esters, polyethoxylated and hydrogenated caster oil, nonionic block copolymers and amphoterics may be used.
This invention relates to a formulation of the pharmaceutical substance minoxidil.
Minoxidil is used for treatment of hereditary hair loss. Previously known formulations comprise a lotion applied using a dropper or by a roller. Minoxidil is sparingly soluble in water and current products comprise propylene glycol, ethanol and water. Such formulations are awkward to administer and thorough coverage of the area to be treated can be difficult.
According to a first aspect of the present invention a pharmaceutical dosage form comprises an active ingredient selected from the group consisting of:-minoxidil, minoxidil sulphate, other soluble minoxidil salts and mixtures thereof;
a surfactant;
water; and optional further excipients;
the formulation being adapted to form a foam when administered by spraying.
Percentages and amounts referred to in the specification are by weight unless stated otherwise. Percentages are selected to total 100%
Dosage forms in accordance with this invention confer several advantages. The absence of ethanol and aerosol prapellents reduces the risk of flammability. Ethanol can be an irritant to a user's skin. The absence of halocarbon aerosol propellents is beneficial to the environment.
Preferably the amount of active ingredient is about 2-5%
Preferably the amount of surfactant is about 2-10% Any combination of anionic, cationic, non-ionic or amphoteric surfactants and non-ionic block copolymers may be used.
Preferably ethoxylated glycerides, ethoxylated sorbitan esters, polyethoxylated and hydrogenated caster oil, nonionic block copolymers and amphoterics may be used.
Especially preferred surfactants may be selected from:-PEG 40 hydrogenated caster oil Polysorbate 20 Cocamidopropyl betaine Glyceryl cocoate PEG 6 caprylic/capric glycerides Poloxamer F 68 Preferred formulations in which the active is minoxidil base include' propylene glycol. An amount of about 50 - 80% is preferred. Propylene glycol is nonessential when the active minoxidil sulphate or other salt.
Preferred formulations include about 20-30% water.
Formulations in accordance with this invention produce a quick breaking foam when sprayed through a fine mesh or nozzle. This allows the foam to be rubbed in easily. The concentration of the active is selected to allow the dose to be administered in a volume of about 0.2-1.0, preferably 0.3-0.6, more preferably about 0.45cm3 of the formulation solution.
Preferred formulations include buffers, pH stabilisers, emollients, skin conditioning agents and other excipients known to those skilled in the art.
According to the second aspect of the second invention, there is provided a spray apparatus comprising a reservoir, metered dose valve and a dosage form in accordance with the first aspect of the present invention.
The invention is further described by means of example, but not in any limitative sense.
Preferred formulations include about 20-30% water.
Formulations in accordance with this invention produce a quick breaking foam when sprayed through a fine mesh or nozzle. This allows the foam to be rubbed in easily. The concentration of the active is selected to allow the dose to be administered in a volume of about 0.2-1.0, preferably 0.3-0.6, more preferably about 0.45cm3 of the formulation solution.
Preferred formulations include buffers, pH stabilisers, emollients, skin conditioning agents and other excipients known to those skilled in the art.
According to the second aspect of the second invention, there is provided a spray apparatus comprising a reservoir, metered dose valve and a dosage form in accordance with the first aspect of the present invention.
The invention is further described by means of example, but not in any limitative sense.
Example 1 A formulation containing minoxidil base was prepared using the following ingredients:
w/v Minoxidil 2.0 Propylene Glycol 70.0 Preservative qs Cocamidopropyl betaine 4.0 as 50% solution Water to 100m1 Example 2 A formulation containing minoxidil sulphate was prepared using the following ingredients:
%w/v 1 S Minoxidil sulphate 2.766 equal to 2.0% as base Preservative qs Cocamidopropyl betaine 2.0 as 50% solution Water to 100rn1 Example 3 Test Method For Evaluation of Foam Quality Equipment ~ Analytical top pan balance - five place with top opening.
Clean 20m1 syringe.
Clamp and clamp stand.
~ 2 clean beakers - one of which must be at least 150m1 volume.
~ Stopwatch.
w/v Minoxidil 2.0 Propylene Glycol 70.0 Preservative qs Cocamidopropyl betaine 4.0 as 50% solution Water to 100m1 Example 2 A formulation containing minoxidil sulphate was prepared using the following ingredients:
%w/v 1 S Minoxidil sulphate 2.766 equal to 2.0% as base Preservative qs Cocamidopropyl betaine 2.0 as 50% solution Water to 100rn1 Example 3 Test Method For Evaluation of Foam Quality Equipment ~ Analytical top pan balance - five place with top opening.
Clean 20m1 syringe.
Clamp and clamp stand.
~ 2 clean beakers - one of which must be at least 150m1 volume.
~ Stopwatch.
Method 1. Position the clamp stand adjacent to the balance.
2. Open the balance top and position the syringe in the clamp directly over the balance S pan.
3. Place a clean empty beaker on the balance pan and either tare the beaker, or record the weight.
4. Take the clean ISOmI beaker and pump at least 100m1 of foam into it.
S. Immediately draw up the foam into the syringe, remove the plunger so that the barrel is full.
6. Immediately place the syringe I the clamp over the tared beaker.
7. Start the stop watch and record the foaxnlsolution that drips from the syringe every minute for a minimum of five minutes.
The weights were plotted against time to give a comparison of foam qualities.
The lower the solution weights were indicative of firmer foams.
The foam quality Was evaluated gravimetrically and it was found that the cocamidopropyl betaine, polysorbate 20 and glyceryl cocoate produced firmer longer lasting foams. The PEG 6 caprylic/capric glycerides, poloxamer F68 and PEG 40 hydrogenated castor oil produced quick breaking foams.
The results are shown in Figure 1.
The product was found to be comparable with the current market products.
2. Open the balance top and position the syringe in the clamp directly over the balance S pan.
3. Place a clean empty beaker on the balance pan and either tare the beaker, or record the weight.
4. Take the clean ISOmI beaker and pump at least 100m1 of foam into it.
S. Immediately draw up the foam into the syringe, remove the plunger so that the barrel is full.
6. Immediately place the syringe I the clamp over the tared beaker.
7. Start the stop watch and record the foaxnlsolution that drips from the syringe every minute for a minimum of five minutes.
The weights were plotted against time to give a comparison of foam qualities.
The lower the solution weights were indicative of firmer foams.
The foam quality Was evaluated gravimetrically and it was found that the cocamidopropyl betaine, polysorbate 20 and glyceryl cocoate produced firmer longer lasting foams. The PEG 6 caprylic/capric glycerides, poloxamer F68 and PEG 40 hydrogenated castor oil produced quick breaking foams.
The results are shown in Figure 1.
The product was found to be comparable with the current market products.
Claims (8)
1. A foamable composition comprising:
- 2-5% minoxidil base;
- 2-10% surfactant;
- 50-80% propylene glycol; and -water;
wherein said composition is free of ethanol and aerosol propellant.
- 2-5% minoxidil base;
- 2-10% surfactant;
- 50-80% propylene glycol; and -water;
wherein said composition is free of ethanol and aerosol propellant.
2. The composition of claim 1 wherein said surfactant comprises an anionic, cationic, non-ionic or amphoteric surfactant or a non ionic block copolymer, or a mixture thereof.
3. The composition of claim 1 wherein said surfactant comprises an ethoxylated glyceride, an ethoxylated sorbitan ester, a polyethoxylated or hydrogenated castor oil, PEG hydrogenated caster oil, Polysorbate 20, cocamidopropyl betaine, glyceryl cocoate, a PEG 6 caprylic/capric glyceride or poloxamer F68, or a mixture thereof.
4. The composition of any one of claims 1-3 further comprising one or more of a buffer, a pH stabilizer, an emollient, or a skin conditioning agent.
5. The composition of any one of claims 1-4 comprising 20-30% of said water.
6. A device for preparing a minoxidil-containing foam, comprising a reservoir, a metered dose valve, and a nozzle, wherein said reservoir contains the composition of any one of claims 1-5.
7. The device of claim 6 wherein said nozzle comprises a mesh.
8. A method of preparing a minoxidil-containing foam, comprising providing the composition of any one of claims 1-5, and spraying said composition through a mesh or nozzle.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0323908.4 | 2003-10-11 | ||
| GBGB0323908.4A GB0323908D0 (en) | 2003-10-11 | 2003-10-11 | Pharmaceutical foam formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2484184A1 CA2484184A1 (en) | 2005-04-11 |
| CA2484184C true CA2484184C (en) | 2012-01-03 |
Family
ID=29433776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2484184A Expired - Fee Related CA2484184C (en) | 2003-10-11 | 2004-10-07 | Minoxidil foam formulation |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20050079139A1 (en) |
| CA (1) | CA2484184C (en) |
| GB (2) | GB0323908D0 (en) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
| WO2004037225A2 (en) | 2002-10-25 | 2004-05-06 | Foamix Ltd. | Cosmetic and pharmaceutical foam |
| IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
| US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
| US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
| US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
| US20060233721A1 (en) * | 2002-10-25 | 2006-10-19 | Foamix Ltd. | Foam containing unique oil globules |
| US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
| US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
| US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
| US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
| US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US20070292461A1 (en) * | 2003-08-04 | 2007-12-20 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
| US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
| US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
| US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
| ZA200507017B (en) * | 2004-02-04 | 2007-03-28 | Foamix Ltd | Cosmetic and pharmaceutical foam with solid matter |
| US20070069046A1 (en) * | 2005-04-19 | 2007-03-29 | Foamix Ltd. | Apparatus and method for releasing a measure of content from a plurality of containers |
| JP2008540511A (en) * | 2005-05-09 | 2008-11-20 | フォーミックス エルティーディー． | Sugar foaming composition |
| US8147815B2 (en) * | 2005-12-16 | 2012-04-03 | Celmatrix Corporation | Topical administration carrier composition and therapeutic formulations comprising same |
| WO2008110872A2 (en) * | 2006-06-23 | 2008-09-18 | Foamix Ltd. | Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses |
| ES2393761T3 (en) * | 2006-07-14 | 2012-12-27 | Stiefel Research Australia Pty Ltd | Pharmaceutical fatty acid foam |
| US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
| US8021649B2 (en) | 2007-02-22 | 2011-09-20 | Cronk Peter J | Continuous spray scalp therapy and dispensing systems for same |
| US20080206156A1 (en) * | 2007-02-22 | 2008-08-28 | Cronk Peter J | Continuous spray scalp therapy and dispensing systems for same |
| PL1986473T3 (en) * | 2007-04-03 | 2017-07-31 | Tsinghua University | Organic electroluminescent device |
| US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| WO2009056991A2 (en) * | 2007-09-04 | 2009-05-07 | Foamix Ltd. | Device for delivery of a foamable composition |
| US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
| WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
| WO2009072007A2 (en) | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
| EP2242476A2 (en) | 2008-01-14 | 2010-10-27 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
| US20120238535A1 (en) * | 2009-02-23 | 2012-09-20 | Smith Jan G | Topical formulation of low level clobetasol propionate for treating disorders of the skin and mucous membranes |
| CA2760186C (en) | 2009-04-28 | 2019-10-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
| CA2752849C (en) | 2009-07-24 | 2014-07-08 | Bernd G. Seigfried | Liquid compositions capable of foaming and including active agents, and methods for making or developing same |
| CA2769625C (en) | 2009-07-29 | 2017-04-11 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
| CA2769677A1 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
| JP5699476B2 (en) * | 2009-08-05 | 2015-04-08 | 大正製薬株式会社 | Hair growth |
| US8945516B2 (en) | 2009-10-02 | 2015-02-03 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
| US20110189114A1 (en) * | 2010-01-29 | 2011-08-04 | Nyangenya Maniga | minoxidil composition and non-aerosol, non-spray foam method of delivery therefor |
| US9271917B2 (en) | 2010-01-29 | 2016-03-01 | Nyangenya Maniga | Method and apparatus for delivery of a measured dosage of a non-aerosol, non-spray foam composition of minoxidil |
| WO2012007843A2 (en) | 2010-07-12 | 2012-01-19 | Foamix Ltd. | Apparatus and method for releasing a unit dose of content from a container |
| US8642097B1 (en) | 2013-03-19 | 2014-02-04 | Nyangenya Maniga | Natural product energy drink and method of use thereof |
| US20160120803A1 (en) * | 2013-06-17 | 2016-05-05 | Contract Pharmaceuticals Limited | Non-aerosol foams for topical administration |
| CA2978573A1 (en) | 2016-09-08 | 2018-03-08 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
| US9962444B2 (en) | 2016-09-27 | 2018-05-08 | Shane Malek | Pharmacokinetically extended action topical hair growth formulation, and administration method |
| WO2019232242A1 (en) | 2018-05-30 | 2019-12-05 | Follica, Inc. | Methods for promoting hair growth |
| DK3886799T3 (en) | 2019-08-07 | 2023-12-18 | Aneira Pharma Inc | COMPOSITIONS FOR THE TREATMENT OF HAIR LOSS |
| BR102021003531A2 (en) | 2021-02-24 | 2022-08-30 | Eurofarma Laboratorios S.A. | FOAMBLE TOPICAL PHARMACEUTICAL COMPOSITION |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3559741A (en) * | 1968-08-08 | 1971-02-02 | Gulf & Western Ind Prod Co | Foam generating apparatus |
| US4139619A (en) * | 1976-05-24 | 1979-02-13 | The Upjohn Company | 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth |
| WO1988001863A1 (en) * | 1986-09-12 | 1988-03-24 | The Upjohn Company | Foams for delivery of minoxidil |
| US5364031A (en) * | 1993-06-10 | 1994-11-15 | The Procter & Gamble Company | Foam dispensing nozzles and dispensers employing said nozzles |
| US5611490A (en) * | 1994-12-19 | 1997-03-18 | Calmar Inc. | Foamer assembly for fluid dispenser |
| US5921447A (en) * | 1997-02-13 | 1999-07-13 | Glaxo Wellcome Inc. | Flow-through metered aerosol dispensing apparatus and method of use thereof |
| AUPP310798A0 (en) * | 1998-04-22 | 1998-05-14 | Soltec Research Pty Ltd | Vehicle system for a composition comprising a piperidinopyrimidine derivative |
| US6524594B1 (en) * | 1999-06-23 | 2003-02-25 | Johnson & Johnson Consumer Companies, Inc. | Foaming oil gel compositions |
| DE60231527D1 (en) * | 2001-10-16 | 2009-04-23 | Toyo Aerosol Ind Co | AEROSOLSPRITZDÜSE |
| EP1342465B1 (en) * | 2002-03-05 | 2011-10-19 | Kao Corporation | Foam-type hair dye and foam-type hair dye discharge container |
| CN1856294A (en) * | 2003-08-25 | 2006-11-01 | 弗米克斯有限公司 | Penetrating pharmaceutical foam |
-
2003
- 2003-10-11 GB GBGB0323908.4A patent/GB0323908D0/en not_active Ceased
-
2004
- 2004-10-01 GB GB0421825A patent/GB2406791B/en not_active Expired - Fee Related
- 2004-10-07 CA CA2484184A patent/CA2484184C/en not_active Expired - Fee Related
- 2004-10-08 US US10/962,292 patent/US20050079139A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| GB0323908D0 (en) | 2003-11-12 |
| GB2406791B (en) | 2008-02-06 |
| US20050079139A1 (en) | 2005-04-14 |
| GB2406791A (en) | 2005-04-13 |
| CA2484184A1 (en) | 2005-04-11 |
| GB0421825D0 (en) | 2004-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2484184C (en) | Minoxidil foam formulation | |
| KR950002879B1 (en) | Foamed aerosol preparation | |
| ES2236352T3 (en) | ANTIMICROBIAL LOTION OF RAPID ACTION OF INCREASED EFFECTIVENESS. | |
| US9107856B2 (en) | Dental appliance cleanser | |
| JP6696768B2 (en) | External composition for screen former | |
| KR20140055689A (en) | Gommage type cosmetic compostion for exfoliating skin having low irritant | |
| JP2020007304A (en) | Skin cleansing spray agent | |
| US20210348087A1 (en) | Liquid detergent having low viscosity | |
| ES2861052T3 (en) | Topical composition comprising oxybutynin for the treatment of hyperhidrosis | |
| JP7245609B2 (en) | external composition | |
| JP4934254B2 (en) | Weakly acidic detergent composition | |
| KR102094626B1 (en) | Liquid for external use | |
| JP5986394B2 (en) | Foam forming aerosol composition | |
| JP2010524888A (en) | Antifungal foam containing ciclopirox olamine and zinc pyrithione and its medical and cosmetic applications | |
| WO2020262151A1 (en) | Skin cleanser composition | |
| KR101874530B1 (en) | Skin cleansing composition ejected with sherbet-like state and article for skin creansing comprising the same | |
| JP2848372B2 (en) | Foam hair treatment agent | |
| JP2020007303A (en) | Skin cleanser composition | |
| JP2020002050A (en) | Skin washing agent composition | |
| JP5777462B2 (en) | Hairdressing mist cosmetics | |
| JP7045750B1 (en) | Alcohol-based rubbing-type hand disinfection composition with improved usability | |
| JP7150050B2 (en) | skin cleanser composition | |
| JP6965444B2 (en) | Skin cleanser composition | |
| JP2018027907A (en) | Oil foam aerosol composition | |
| JPH0457642B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20181009 |